Long-term outcomes of accelerated BEP (bleomycin, etoposide, cisplatin) for advanced germ cell tumours: updated analysis of an Australian multicentre phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)

Ann Oncol. 2016 Dec;27(12):2302-2303. doi: 10.1093/annonc/mdw313. Epub 2016 Aug 8.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
  • Australia / epidemiology
  • Bleomycin / administration & dosage
  • Cisplatin / administration & dosage
  • Clinical Trials, Phase II as Topic*
  • Etoposide / administration & dosage
  • Female
  • Humans
  • Male
  • Multicenter Studies as Topic*
  • Neoplasms, Germ Cell and Embryonal / diagnosis
  • Neoplasms, Germ Cell and Embryonal / drug therapy*
  • Neoplasms, Germ Cell and Embryonal / epidemiology
  • New Zealand / epidemiology
  • Prostatic Neoplasms / diagnosis
  • Prostatic Neoplasms / drug therapy*
  • Prostatic Neoplasms / epidemiology
  • Time Factors
  • Treatment Outcome
  • Urogenital Neoplasms / diagnosis
  • Urogenital Neoplasms / drug therapy*
  • Urogenital Neoplasms / epidemiology

Substances

  • Bleomycin
  • Etoposide
  • Cisplatin